Views & Analysis Harnessing behavioural science for smart communications Behavioural science can be applied to inform and improve outcomes all round.
Views & Analysis Orphan drugs: overcoming barriers to market access What manufacturers should consider, after successfully overcoming any HTA hurdles, to achieve market access.
Views & Analysis Patient personas can help drive behaviour change Creating patient personas from large data sets can drive greater understanding of patients' behaviours.
Views & Analysis Creating headroom: can cutting spend on low-value prescripti... Can reducing NHS spending on 'low-value' prescriptions help fund new drugs?
Views & Analysis Health data security: report’s implications for pharma Data security issues that could have an impact on the pharma industry.
Views & Analysis Social media listening: uncovering patients’ needs Conversations on social media can provide unprecedented patient insights.
Digital On AI and computational support of biochemistry, with Alan R... Dr Alan Roth, CEO of Oxford Drug Design, discusses the use of AI to accelerate discovery of new treatments.
Sales & Marketing Sponsored The AI imperative: Establishing the standard for modern clin... The findings from the Medidata-commissioned survey confirm that AI implementation in clinical trials has moved firmly beyond theoretical discussion.
